284462-77-7Relevant articles and documents
Discovery and characterization of the N-phenyl-N′-naphthylurea class of p38 kinase inhibitors
Cirillo, Pier F.,Hickey, Eugene R.,Moss, Neil,Breitfelder, Steffen,Betageri, Raj,Fadra, Tazmeen,Gaenzler, Faith,Gilmore, Thomas,Goldberg, Daniel R.,Kamhi, Victor,Kirrane, Thomas,Kroe, Rachel R.,Madwed, Jeffrey,Moriak, Monica,Netherton, Matthew,Pargellis, Christopher A.,Patel, Usha R.,Qian, Kevin C.,Sharma, Rajiv,Sun, Sanxing,Swinamer, Alan,Torcellini, Carol,Takahashi, Hidenori,Tsang, Michele,Xiong, Zhaoming
scheme or table, p. 2386 - 2391 (2009/12/07)
An effort aimed at exploring structural diversity in the N-pyrazole-N′-naphthylurea class of p38 kinase inhibitors led to the synthesis and characterization of N-phenyl-N′-naphthylureas. Examples of these compounds displayed excellent inhibition of TNF-α production in vitro, as well as efficacy in a mouse model of lipopolysaccharide induced endotoxemia. In addition, perspective is provided on the role of a sulfonamide functionality in defining inhibitor potency.
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
-
, (2008/06/13)
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
-
, (2008/06/13)
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
-
Page/Page column 23, (2010/01/31)
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
-
, (2008/06/13)
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
-
, (2008/06/13)
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.